Key articles and guidelines in the management of pulmonary arterial hypertension

2011 update.

Samuel G. Johnson, Steven R. Kayser, Rebecca L. Attridge, Laura Duvall, Tyree H. Kiser, Rebecca Moote, Brent N. Reed, J. E. Rodgers, Brian L Erstad

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Pharmacotherapeutic approaches for the management of pulmonary arterial hypertension (PAH) have expanded greatly in the last 10 years. Pulmonary arterial hypertension is a relatively rare disease and is associated with myriad disease processes. The older term for PAH, primary PAH, has been changed to represent these differences and to distinguish it from postcapillary PAH associated with left-sided heart failure. Limitations in evaluating treatment approaches for PAH include its rarity, the small number of patients included in clinical trials, and issues regarding the use of placebo-controlled trials in a disease with such a high mortality rate if left untreated. Management options include the use of prostacyclin and prostacyclin analogues, endothelin receptor antagonists, and phosphodiesterase inhibitors, as well as traditional background therapy with diuretics, digoxin, calcium channel blockers, and warfarin. Numerous drugs are under investigation to evaluate their possible roles in management. Combination therapy is increasingly becoming a standard approach to therapy, with mounting literature to document effectiveness. Current or emerging roles for the pharmacist in the management of PAH largely involves ensuring access to drug therapy, facilitating specialty pharmacy dispensing, and providing patient counseling. Newer roles may include future drug development, optimized use of investigational drugs, and specialized disease management programs. This compilation includes a series of articles identifying important literature in cardiovascular pharmacotherapy. This bibliography focuses on pharmacotherapeutic management of pulmonary arterial hypertension (PAH). Most of the cited works present the results of significant human clinical studies that have shaped the management of patients with PAH. Limited primary literature is available for some topics, so in addition, consensus documents prepared by expert panels are reviewed. This compilation may serve as a teaching tool, reference resource, or update of the literature for pharmacy clinicians, physicians, and students.

Original languageEnglish (US)
JournalPharmacotherapy
Volume32
Issue number6
StatePublished - Jun 2012
Externally publishedYes

Fingerprint

Pulmonary Hypertension
Guidelines
Epoprostenol
Investigational Drugs
Drug Therapy
Phosphodiesterase Inhibitors
Digoxin
Calcium Channel Blockers
Bibliography
Warfarin
Therapeutics
Disease Management
Rare Diseases
Pharmacists
Diuretics
Pharmaceutical Preparations
Counseling
Consensus
Teaching
Heart Failure

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

Johnson, S. G., Kayser, S. R., Attridge, R. L., Duvall, L., Kiser, T. H., Moote, R., ... Erstad, B. L. (2012). Key articles and guidelines in the management of pulmonary arterial hypertension: 2011 update. Pharmacotherapy, 32(6).

Key articles and guidelines in the management of pulmonary arterial hypertension : 2011 update. / Johnson, Samuel G.; Kayser, Steven R.; Attridge, Rebecca L.; Duvall, Laura; Kiser, Tyree H.; Moote, Rebecca; Reed, Brent N.; Rodgers, J. E.; Erstad, Brian L.

In: Pharmacotherapy, Vol. 32, No. 6, 06.2012.

Research output: Contribution to journalArticle

Johnson, SG, Kayser, SR, Attridge, RL, Duvall, L, Kiser, TH, Moote, R, Reed, BN, Rodgers, JE & Erstad, BL 2012, 'Key articles and guidelines in the management of pulmonary arterial hypertension: 2011 update.', Pharmacotherapy, vol. 32, no. 6.
Johnson SG, Kayser SR, Attridge RL, Duvall L, Kiser TH, Moote R et al. Key articles and guidelines in the management of pulmonary arterial hypertension: 2011 update. Pharmacotherapy. 2012 Jun;32(6).
Johnson, Samuel G. ; Kayser, Steven R. ; Attridge, Rebecca L. ; Duvall, Laura ; Kiser, Tyree H. ; Moote, Rebecca ; Reed, Brent N. ; Rodgers, J. E. ; Erstad, Brian L. / Key articles and guidelines in the management of pulmonary arterial hypertension : 2011 update. In: Pharmacotherapy. 2012 ; Vol. 32, No. 6.
@article{f87f260f66db48e4914b63d5a76c7a97,
title = "Key articles and guidelines in the management of pulmonary arterial hypertension: 2011 update.",
abstract = "Pharmacotherapeutic approaches for the management of pulmonary arterial hypertension (PAH) have expanded greatly in the last 10 years. Pulmonary arterial hypertension is a relatively rare disease and is associated with myriad disease processes. The older term for PAH, primary PAH, has been changed to represent these differences and to distinguish it from postcapillary PAH associated with left-sided heart failure. Limitations in evaluating treatment approaches for PAH include its rarity, the small number of patients included in clinical trials, and issues regarding the use of placebo-controlled trials in a disease with such a high mortality rate if left untreated. Management options include the use of prostacyclin and prostacyclin analogues, endothelin receptor antagonists, and phosphodiesterase inhibitors, as well as traditional background therapy with diuretics, digoxin, calcium channel blockers, and warfarin. Numerous drugs are under investigation to evaluate their possible roles in management. Combination therapy is increasingly becoming a standard approach to therapy, with mounting literature to document effectiveness. Current or emerging roles for the pharmacist in the management of PAH largely involves ensuring access to drug therapy, facilitating specialty pharmacy dispensing, and providing patient counseling. Newer roles may include future drug development, optimized use of investigational drugs, and specialized disease management programs. This compilation includes a series of articles identifying important literature in cardiovascular pharmacotherapy. This bibliography focuses on pharmacotherapeutic management of pulmonary arterial hypertension (PAH). Most of the cited works present the results of significant human clinical studies that have shaped the management of patients with PAH. Limited primary literature is available for some topics, so in addition, consensus documents prepared by expert panels are reviewed. This compilation may serve as a teaching tool, reference resource, or update of the literature for pharmacy clinicians, physicians, and students.",
author = "Johnson, {Samuel G.} and Kayser, {Steven R.} and Attridge, {Rebecca L.} and Laura Duvall and Kiser, {Tyree H.} and Rebecca Moote and Reed, {Brent N.} and Rodgers, {J. E.} and Erstad, {Brian L}",
year = "2012",
month = "6",
language = "English (US)",
volume = "32",
journal = "Pharmacotherapy",
issn = "0277-0008",
publisher = "Pharmacotherapy Publications Inc.",
number = "6",

}

TY - JOUR

T1 - Key articles and guidelines in the management of pulmonary arterial hypertension

T2 - 2011 update.

AU - Johnson, Samuel G.

AU - Kayser, Steven R.

AU - Attridge, Rebecca L.

AU - Duvall, Laura

AU - Kiser, Tyree H.

AU - Moote, Rebecca

AU - Reed, Brent N.

AU - Rodgers, J. E.

AU - Erstad, Brian L

PY - 2012/6

Y1 - 2012/6

N2 - Pharmacotherapeutic approaches for the management of pulmonary arterial hypertension (PAH) have expanded greatly in the last 10 years. Pulmonary arterial hypertension is a relatively rare disease and is associated with myriad disease processes. The older term for PAH, primary PAH, has been changed to represent these differences and to distinguish it from postcapillary PAH associated with left-sided heart failure. Limitations in evaluating treatment approaches for PAH include its rarity, the small number of patients included in clinical trials, and issues regarding the use of placebo-controlled trials in a disease with such a high mortality rate if left untreated. Management options include the use of prostacyclin and prostacyclin analogues, endothelin receptor antagonists, and phosphodiesterase inhibitors, as well as traditional background therapy with diuretics, digoxin, calcium channel blockers, and warfarin. Numerous drugs are under investigation to evaluate their possible roles in management. Combination therapy is increasingly becoming a standard approach to therapy, with mounting literature to document effectiveness. Current or emerging roles for the pharmacist in the management of PAH largely involves ensuring access to drug therapy, facilitating specialty pharmacy dispensing, and providing patient counseling. Newer roles may include future drug development, optimized use of investigational drugs, and specialized disease management programs. This compilation includes a series of articles identifying important literature in cardiovascular pharmacotherapy. This bibliography focuses on pharmacotherapeutic management of pulmonary arterial hypertension (PAH). Most of the cited works present the results of significant human clinical studies that have shaped the management of patients with PAH. Limited primary literature is available for some topics, so in addition, consensus documents prepared by expert panels are reviewed. This compilation may serve as a teaching tool, reference resource, or update of the literature for pharmacy clinicians, physicians, and students.

AB - Pharmacotherapeutic approaches for the management of pulmonary arterial hypertension (PAH) have expanded greatly in the last 10 years. Pulmonary arterial hypertension is a relatively rare disease and is associated with myriad disease processes. The older term for PAH, primary PAH, has been changed to represent these differences and to distinguish it from postcapillary PAH associated with left-sided heart failure. Limitations in evaluating treatment approaches for PAH include its rarity, the small number of patients included in clinical trials, and issues regarding the use of placebo-controlled trials in a disease with such a high mortality rate if left untreated. Management options include the use of prostacyclin and prostacyclin analogues, endothelin receptor antagonists, and phosphodiesterase inhibitors, as well as traditional background therapy with diuretics, digoxin, calcium channel blockers, and warfarin. Numerous drugs are under investigation to evaluate their possible roles in management. Combination therapy is increasingly becoming a standard approach to therapy, with mounting literature to document effectiveness. Current or emerging roles for the pharmacist in the management of PAH largely involves ensuring access to drug therapy, facilitating specialty pharmacy dispensing, and providing patient counseling. Newer roles may include future drug development, optimized use of investigational drugs, and specialized disease management programs. This compilation includes a series of articles identifying important literature in cardiovascular pharmacotherapy. This bibliography focuses on pharmacotherapeutic management of pulmonary arterial hypertension (PAH). Most of the cited works present the results of significant human clinical studies that have shaped the management of patients with PAH. Limited primary literature is available for some topics, so in addition, consensus documents prepared by expert panels are reviewed. This compilation may serve as a teaching tool, reference resource, or update of the literature for pharmacy clinicians, physicians, and students.

UR - http://www.scopus.com/inward/record.url?scp=84871882929&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84871882929&partnerID=8YFLogxK

M3 - Article

VL - 32

JO - Pharmacotherapy

JF - Pharmacotherapy

SN - 0277-0008

IS - 6

ER -